급성 림프구성 백혈병 치료제 시장 : 용도별, 약제별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율 예측(2023-2030년)

Acute Lymphoblastic Leukemia Therapeutics Market, By Application, By Drug, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030

US $ 3,250 ￦ 4,518,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 4,650 ￦ 6,464,000

PDF (5 User License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 5,650 ￦ 7,855,000

PDF & Excel (Enterprise User License)

PDF & Excel 보고서를 동일 기업 내 모든 사용자가 사용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

보고서 하이라이트

급성 림프구성 백혈병 치료제 시장 규모는 2022년 37억 9,420만 달러로 평가되었고, 2023년부터 2030년까지 CAGR 5.7%로 확대될 전망입니다.

급성 림프구성 백혈병 치료제 시장-시장 역학

급성 림프구성 백혈병의 이환율 증가와 세계 골수 생검의 급증이 시장 수요를 촉진할 것으로 예상됩니다.

시장은 급성 림프구성 백혈병의 이환율 증가와 세계 골수 생검의 급증으로 성장을 보여줍니다. 게다가 백혈병 연구에 대한 투자 증가와 국민들 사이에서 표적 치료에 대한 인식이 높아지고 있는 것도 시장 확대의 원동력이 되고 있습니다. 그러나 규제 당국의 엄격한 승인과 부작용이 과제가 되고 있습니다. 주요 치료제의 특허 부족과 치료비 상승도 시장 성장을 제한하고 있습니다. 그러나 임상시험 증가 및 신제품의 승인은 신흥국 시장과 선진국 시장에 기회를 가져왔습니다.

급성 림프구성 백혈병 치료제 시장-주요 인사이트력

우리의 리서치 애널리스트가 공유한 분석에 따르면 세계의 급성 림프구성 백혈병 치료제 시장은 예측 기간(2023-2030년)에 약 5.7%의 연평균 복합 성장률(CAGR)로 매년 성장할 것으로 예측됩니다.

급성 림프구성 백혈병 치료제 시장은 급성 림프구성 백혈병의 이환율 증가와 세계 골수 생검의 급증으로 견인되어 현저한 속도로 성장할 것으로 예측됩니다.

용도별로 소아과 분야가 2022년 최대 시장 점유율을 나타낸 것으로 평가되었습니다.

약물별로 하이퍼 CVAD 요법은 2022년 주요 부문이었습니다.

지역별로는 북미가 2022년 주요 수익원이었습니다.

급성 림프구성 백혈병 치료제 시장-세분화 분석 :

세계의 급성 림프구성 백혈병 치료제 시장은 용도별, 약제별, 지역별로 구분됩니다.

용도에 따라 시장은 소아과 및 성인의 두 부문으로 나뉩니다. 소아과 영역이 가장 높은 수익을 올리고 있으며 예측 기간 동안에도 주도적 지위를 유지할 것으로 예상됩니다. 이것은 주로 소아 인구 사이에서 급성 림프구성 및 림프구성 백혈병의 발병률이 증가하고 있기 때문입니다. 급성 림프구성 및 림프구성 백혈병은 소아층에서 가장 이환율이 높은 암종 중 하나입니다. 또한, 소아 환자는 급성 림프구성 및 림프구성 백혈병 치료의 성공률이 높고, 이 부문의 우위성을 더욱 견고하게 하고 있습니다.

시장은 약물별로 6개의 부문으로 분류됩니다. 하이퍼 CVAD 레지멘, 링커 레지멘, 뉴클레오시드 대사 억제제(크롤러나 네라라빈 등), 표적 약물 및 면역 요법, CALGB 8811 레지멘, 온커스퍼입니다. 이 중 하이퍼 CVAD 요법은 ALL 치료에 대한 광범위한 사용으로 2022년 급성 림프구성 및 림프구성 백혈병 치료제 시장에서 지배적인 선수로 부상했습니다. Hyper-CVAD 요법은 급성 림프구성 및 림프구성 백혈병에 가장 자주 사용되는 치료법 중 하나로 널리 알려져 있습니다.

급성 림프구성 백혈병 치료제 시장-지리적 인사이트

지리적으로, 이 시장은 북미, 라틴아메리카, 유럽, 아시아태평양, 중동 및 아프리카의 각 지역으로 퍼져 있습니다. 이 지역은 비즈니스를 제공하는 국가에 의해 더 나뉩니다.

급성 림프구성 백혈병 치료제 시장-경쟁 구도 :

급성 림프구성 백혈병 치료제 분야의 기업들은 치료 옵션을 넓히기 위해 연구 개발에 적극적으로 노력하고 있습니다. 이러한 기업들은 ALL의 특정 측면을 목표로 하는 신규 약제 및 치료법의 발견에 투자하여 효능 향상과 부작용 완화를 목표로 하고 있습니다. 헬스케어 기관이나 학술연구 센터와의 연계를 통해 임상시험 및 혁신적인 치료법의 개발이 촉진되고 있습니다. 또한 특히 신흥 시장에서 이러한 치료법의 입수성과 구매 용이성을 향상시키기 위한 노력도 하고 있습니다. 또한 기업은 환자의 안전을 보장하기 위해 규제 당국의 승인과 엄격한 품질 기준 준수를 우선시합니다. 전반적인 목표는 ALL 치료제의 전망을 지속적으로 진화시키고 이 과제와 싸우는 환자에게 희망과 더 나은 결과를 제공하는 것입니다.

목차

제1장 급성 림프구성 백혈병 치료제 시장 개요

• 조사 범위
• 시장 추정 연도

제2장 주요 요약

• 시장 분석
• 경쟁 인사이트

제3장 급성 림프구성 백혈병 치료제의 주요 시장 동향

• 시장 성장 촉진요인
• 시장 성장 억제요인
• 시장 기회
• 향후 시장 동향

제4장 급성 림프구성 백혈병 치료제 업계의 조사

• PEST 분석
• Porter's Five Forces 분석
• 성장 전망 맵핑
• 규제 틀의 분석

제5장 급성 림프구성 백혈병 치료제 시장 : COVID-19의 영향 분석

• 신형 코로나 바이러스 감염의 이전 영향 분석
• 신형 코로나 바이러스 감염의 포스트 영향 분석

제6장 급성 림프구성 백혈병 치료제 시장 상황

• 급성 림프구성 백혈병 치료제 시장 점유율 분석(2022년)
• 주요 제조업체별 분석 데이터
  • 기존 기업의 분석
  • 신흥 기업의 분석

제7장 급성 림프구성 백혈병 치료제 시장 : 용도별

• 개요
  • 용도별 부문 점유율 분석
  • 소아
  • 성인

제8장 급성 림프구성 백혈병 치료제 시장 : 약제별

• 개요
  • 약제별 부문 점유율 분석
  • 하이퍼 CVAD 레지멘
  • 링커 처방
  • 뉴클레오시드 대사 억제제(클로라 및 네라라빈)
  • 표적 약물 및 면역 요법
  • CALGB 8811 처방
  • 온카스파

제9장 급성 림프구성 백혈병 치료제 시장 : 지역별

• 서문
• 북미
  • 개요
  • 북미의 주요 제조업체
  • 미국
  • 캐나다
• 유럽
  • 개요
  • 유럽의 주요 제조업체
  • 독일
  • 이탈리아
  • 영국
  • 프랑스
  • 러시아
  • 네덜란드
  • 스웨덴
  • 폴란드
  • 기타
• 아시아태평양(APAC)
  • 개요
  • 아시아태평양의 주요 제조업체
  • 인도
  • 중국
  • 일본
  • 한국
  • 호주
  • 태국
  • 인도네시아
  • 필리핀
  • 기타
• 라틴아메리카
  • 개요
  • 라틴아메리카의 주요 제조업체
  • 브라질
  • 멕시코
  • 아르헨티나
  • 콜롬비아
  • 기타
• 중동 및 아프리카
  • 개요
  • 중동 및 아프리카의 주요 제조업체
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 이스라엘
  • 터키
  • 알제리
  • 이집트
  • 기타

제10장 주요 벤더 분석-급성 림프구성 백혈병 치료제 업계

• 경쟁 대시보드
• 기업 프로파일
  • Amgen, Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Erytech Pharma, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Kite Pharma, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Spectrum

제11장 애널리스트의 전방위 전망

AJY

영문 목차

영문목차

REPORT HIGHLIGHT

Acute Lymphoblastic Leukemia Therapeutics Market size was valued at USD 3,794.2 Million in 2022, expanding at a CAGR of 5.7% from 2023 to 2030.

Acute lymphocytic/lymphoblastic leukemia is a cancer type originating from immature lymphocytes. The term "acute" denotes its rapid progression and spread throughout the body, originating in the bone marrow and swiftly infiltrating other vital organs like the liver, spleen, lymph nodes, central nervous system, and bloodstream. Symptoms may include fatigue, pallor, easy bruising, gum and nosebleeds, weight loss, shortness of breath, and loss of appetite. Multiple therapeutic approaches, including chemotherapy, are utilized in ALL treatment.

Acute Lymphoblastic Leukemia Therapeutics Market- Market Dynamics

Increasing incidence of acute lymphoblastic leukemia and a surge in global bone marrow biopsies is expected to propel the market demand

The market is witnessing growth due to the increasing incidence of acute lymphoblastic leukemia and a surge in global bone marrow biopsies. Additionally, heightened investments in leukemia research and growing awareness of targeted therapies among the population are driving market expansion. However, stringent regulatory approvals and adverse drug side effects pose challenges. Patent expirations of key treatment drugs and elevated therapy costs also limit market growth. Nonetheless, increasing clinical trials and new product approvals offer opportunities in emerging and developed markets.

Acute Lymphoblastic Leukemia Therapeutics Market- Key Insights

As per the analysis shared by our research analyst, the global Acute Lymphoblastic Leukemia Therapeutics Market is estimated to grow annually at a CAGR of around 5.7% over the forecast period (2023-2030)

The Acute Lymphoblastic Leukemia Therapeutics Market is projected to grow at a significant rate driven by increasing incidence of acute lymphoblastic leukemia and a surge in global bone marrow biopsies

Based on Application, the pediatrics segment was predicted to show maximum market share in the year 2022

Based on Drug, Hyper -CVAD Regimen was the leading Segment in 2022

On the basis of region, North America was the leading revenue generator in 2022

Acute Lymphoblastic Leukemia Therapeutics Market- Segmentation Analysis:

The Global Acute Lymphoblastic Leukemia Therapeutics Market is segmented on the basis of Application, By Drug, and Region.

Based on the application, the market is divided into two segments: pediatrics and adults. The pediatrics segment generated the highest revenue, and it is expected to maintain its leading position throughout the forecast period. This is primarily attributed to the elevated incidence of acute lymphocytic/lymphoblastic leukemia among the pediatric population. Acute lymphocytic/lymphoblastic leukemia ranks as one of the most prevalent cancer types in the pediatric demographic. Furthermore, pediatric patients exhibit a higher success rate in acute lymphocytic/lymphoblastic leukemia treatments, further solidifying the segment's dominance.

The market is categorized by Drug into six segments: Hyper-CVAD Regimen, Linker Regimen, Nucleoside Metabolic Inhibitors (such as Clolar and Nelarabine), Targeted Drugs & Immunotherapy, CALGB 8811 Regimen, and Oncaspar. Among these, the Hyper-CVAD Regimen emerged as the dominant player in the acute lymphocytic/lymphoblastic leukemia therapeutics market in 2022 due to its extensive utilization in ALL treatment. The Hyper-CVAD Regimen is widely recognized as one of the most frequently employed therapeutic options for acute lymphocytic/lymphoblastic leukemia.

Acute Lymphoblastic Leukemia Therapeutics Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

Acute Lymphoblastic Leukemia Therapeutics Market- Competitive Landscape:

Companies in the Acute Lymphoblastic Leukemia therapeutics sector are actively engaged in research and development to advance treatment options. They invest in the discovery of novel drugs and therapies that target specific aspects of ALL, aiming for improved efficacy and reduced side effects. Collaborations with healthcare institutions and academic research centers facilitate clinical trials and the development of innovative treatments. Efforts are also directed towards enhancing the accessibility and affordability of these treatments, particularly in emerging markets. Furthermore, companies prioritize regulatory approvals and adherence to stringent quality standards to ensure patient safety. Overall, their goal is to continue evolving the landscape of ALL therapeutics, offering hope and better outcomes for patients battling this challenging disease.

Recent Developments:

In May 2023, Shorla Oncology, a pharmaceutical company based in the United States and Ireland, in collaboration with EVERSANA, a leading provider of commercialization services for the life science sector, officially initiated the commercial release of Nelarabine Injection. This drug is intended for the treatment of T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma (T-LBL) in both adult and pediatric patients aged one year and older who have not experienced a positive response to, or have experienced relapse following treatment with, a minimum of two chemotherapy regimens.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA THERAPEUTICS MARKET KEY PLAYERS

• Amgen, Inc.
• Bristol-Myers Squibb Company
• Celgene Corporation
• Erytech Pharma, Inc.
• F. Hoffmann-La Roche Ltd.
• Kite Pharma, Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi
• Spectrum

GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA THERAPEUTICS MARKET, BY APPLICATION

• Pediatrics
• Adults

GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA THERAPEUTICS MARKET, BY DRUG

• Hyper-CVAD Regimen
• Linker Regimen
• Nucleoside Metabolic Inhibitors (Clolar and Nelarabine)
• Targeted Drugs & Immunotherapy
• CALGB 8811 Regimen
• Oncaspa

GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA THERAPEUTICS MARKET, BY REGION

• North America
• The U.S.
• Canada
• Europe
• Germany
• France
• Italy
• Spain
• United Kingdom
• Russia
• Netherlands
• Sweden
• Poland
• Rest of Europe
• Asia Pacific
• India
• China
• South Korea
• Japan
• Australia
• Thailand
• Indonesia
• Philippines
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of LATAM
• The Middle East and Africa
• Saudi Arabia
• United Arab Emirates
• Israel
• Turkey
• Algeria
• Egypt
• Rest of MEA

Table of Contents

1. Acute Lymphoblastic Leukemia Therapeutics Market Overview

• 1.1. Study Scope
• 1.2. Market Estimation Years

2. Executive Summary

• 2.1. Market Snippet
  • 2.1.1. Acute Lymphoblastic Leukemia Therapeutics Market Snippet by Application
  • 2.1.2. Acute Lymphoblastic Leukemia Therapeutics Market Snippet by Drug
  • 2.1.3. Acute Lymphoblastic Leukemia Therapeutics Market Snippet by Country
  • 2.1.4. Acute Lymphoblastic Leukemia Therapeutics Market Snippet by Region
• 2.2. Competitive Insights

3. Acute Lymphoblastic Leukemia Therapeutics Key Market Trends

• 3.1. Acute Lymphoblastic Leukemia Therapeutics Market Drivers
  • 3.1.1. Impact Analysis of Market Drivers
• 3.2. Acute Lymphoblastic Leukemia Therapeutics Market Restraints
  • 3.2.1. Impact Analysis of Market Restraints
• 3.3. Acute Lymphoblastic Leukemia Therapeutics Market Opportunities
• 3.4. Acute Lymphoblastic Leukemia Therapeutics Market Future Trends

4. Acute Lymphoblastic Leukemia Therapeutics Industry Study

• 4.1. PEST Analysis
• 4.2. Porter's Five Forces Analysis
• 4.3. Growth Prospect Mapping
• 4.4. Regulatory Framework Analysis

5. Acute Lymphoblastic Leukemia Therapeutics Market: COVID-19 Impact Analysis

• 5.1. Pre-COVID-19 Impact Analysis
• 5.2. Post-COVID-19 Impact Analysis
  • 5.2.1. Top Performing Segments
  • 5.2.2. Marginal Growth Segments
  • 5.2.3. Top Looser Segments
  • 5.2.4. Marginal Loss Segments

6. Acute Lymphoblastic Leukemia Therapeutics Market Landscape

• 6.1. Acute Lymphoblastic Leukemia Therapeutics Market Share Analysis, 2022
• 6.2. Breakdown Data, by Key Manufacturer
  • 6.2.1. Established Players' Analysis
  • 6.2.2. Emerging Players' Analysis

7. Acute Lymphoblastic Leukemia Therapeutics Market - By Application

• 7.1. Overview
  • 7.1.1. Segment Share Analysis, By Application, 2022 & 2030 (%)
  • 7.1.2. Pediatrics
  • 7.1.3. Adults

8. Acute Lymphoblastic Leukemia Therapeutics Market - By Drug

• 8.1. Overview
  • 8.1.1. Segment Share Analysis, By Drug, 2022 & 2030 (%)
  • 8.1.2. Hyper-CVAD Regimen
  • 8.1.3. Linker Regimen
  • 8.1.4. Nucleoside Metabolic Inhibitors (Clolar and Nelarabine)
  • 8.1.5. Targeted Drugs & Immunotherapy
  • 8.1.6. CALGB 8811 Regimen
  • 8.1.7. Oncaspa

9. Acute Lymphoblastic Leukemia Therapeutics Market- By Geography

• 9.1. Introduction
  • 9.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
• 9.2. North America
  • 9.2.1. Overview
  • 9.2.2. Acute Lymphoblastic Leukemia Therapeutics Key Manufacturers in North America
  • 9.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 9.2.4. North America Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 9.2.5. North America Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.2.6. U.S.
    • 9.2.6.1. Overview
    • 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.2.6.3. U.S. Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.2.6.4. U.S. Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.2.7. Canada
    • 9.2.7.1. Overview
    • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.2.7.3. Canada Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.2.7.4. Canada Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
• 9.3. Europe
  • 9.3.1. Overview
  • 9.3.2. Acute Lymphoblastic Leukemia Therapeutics Key Manufacturers in Europe
  • 9.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 9.3.4. Europe Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 9.3.5. Europe Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.3.6. Germany
    • 9.3.6.1. Overview
    • 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.3.6.3. Germany Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.3.6.4. Germany Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.3.7. Italy
    • 9.3.7.1. Overview
    • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.3.7.3. Italy Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.3.7.4. Italy Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.3.8. United Kingdom
    • 9.3.8.1. Overview
    • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.3.8.3. United Kingdom Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.3.8.4. United Kingdom Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.3.9. France
    • 9.3.9.1. Overview
    • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.3.9.3. France Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.3.9.4. France Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.3.10. Russia
    • 9.3.10.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.3.10.2. Russia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.3.10.3. Russia Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.3.11. Netherlands
    • 9.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.3.11.2. Netherlands Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.3.11.3. Netherlands Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.3.12. Sweden
    • 9.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.3.12.2. Sweden Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.3.12.3. Sweden Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.3.13. Poland
    • 9.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.3.13.2. Poland Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.3.13.3. Poland Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.3.14. Rest of Europe
    • 9.3.14.1. Overview
    • 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.3.14.3. Rest of the Europe Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.3.14.4. Rest of the Europe Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
• 9.4. Asia Pacific (APAC)
  • 9.4.1. Overview
  • 9.4.2. Acute Lymphoblastic Leukemia Therapeutics Key Manufacturers in Asia Pacific
  • 9.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 9.4.4. Asia Pacific Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 9.4.5. Asia Pacific Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.4.6. India
    • 9.4.6.1. Overview
    • 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.4.6.3. India Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.4.6.4. India Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.4.7. China
    • 9.4.7.1. Overview
    • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.4.7.3. China Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.4.7.4. China Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.4.8. Japan
    • 9.4.8.1. Overview
    • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.4.8.3. Japan Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.4.8.4. Japan Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.4.9. South Korea
    • 9.4.9.1. Overview
    • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.4.9.3. South Korea Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.4.9.4. South Korea Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.4.10. Australia
    • 9.4.10.1. Overview
    • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.4.10.3. Australia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.4.10.4. Australia Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.4.11. Thailand
    • 9.4.11.1. Overview
    • 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.4.11.3. Thailand Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.4.11.4. Thailand Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.4.12. Indonesia
    • 9.4.12.1. Overview
    • 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.4.12.3. Indonesia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.4.12.4. Indonesia Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.4.13. Philippines
    • 9.4.13.1. Overview
    • 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.4.13.3. Philippines Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.4.13.4. Philippines Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.4.14. Rest of APAC
    • 9.4.14.1. Overview
    • 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.4.14.3. Rest of APAC Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.4.14.4. Rest of APAC Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
• 9.5. Latin America
  • 9.5.1. Overview
  • 9.5.2. Acute Lymphoblastic Leukemia Therapeutics Key Manufacturers in Latin America
  • 9.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 9.5.4. Latin America Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 9.5.5. Latin America Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.5.6. Brazil
    • 9.5.6.1. Overview
    • 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.5.6.3. Brazil Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.5.6.4. Brazil Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.5.7. Mexico
    • 9.5.7.1. Overview
    • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.5.7.3. Mexico Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.5.7.4. Mexico Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.5.8. Argentina
    • 9.5.8.1. Overview
    • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.5.8.3. Argentina Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.5.8.4. Argentina Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.5.9. Colombia
    • 9.5.9.1. Overview
    • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.5.9.3. Colombia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.5.9.4. Colombia Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.5.10. Rest of LATAM
    • 9.5.10.1. Overview
    • 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.5.10.3. Rest of LATAM Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.5.10.4. Rest of LATAM Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
• 9.6. Middle East and Africa
  • 9.6.1. Overview
  • 9.6.2. Acute Lymphoblastic Leukemia Therapeutics Key Manufacturers in Middle East and Africa
  • 9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 9.6.4. Middle East and Africa Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 9.6.5. Middle East and Africa Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.6.6. Saudi Arabia
    • 9.6.6.1. Overview
    • 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.6.6.3. Saudi Arabia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.6.6.4. Saudi Arabia Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.6.7. United Arab Emirates
    • 9.6.7.1. Overview
    • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.6.7.3. United Arab Emirates Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.6.7.4. United Arab Emirates Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.6.8. Israel
    • 9.6.8.1. Overview
    • 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.6.8.3. Israel Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.6.8.4. Israel Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.6.9. Turkey
    • 9.6.9.1. Overview
    • 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.6.9.3. Turkey Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.6.9.4. Turkey Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.6.10. Algeria
    • 9.6.10.1. Overview
    • 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.6.10.3. Algeria Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.6.10.4. Algeria Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.6.11. Egypt
    • 9.6.11.1. Overview
    • 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.6.11.3. Egypt Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.6.11.4. Egypt Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.6.12. Rest of MEA
    • 9.6.12.1. Overview
    • 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.6.12.3. Rest of MEA Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.6.12.4. Rest of MEA Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)

10. Key Vendor Analysis- Acute Lymphoblastic Leukemia Therapeutics Industry

• 10.1. Competitive Dashboard
• 10.2. Company Profiles
  • 10.2.1. Amgen, Inc.
  • 10.2.2. Bristol-Myers Squibb Company
  • 10.2.3. Celgene Corporation
  • 10.2.4. Erytech Pharma, Inc.
  • 10.2.5. F. Hoffmann-La Roche Ltd.
  • 10.2.6. Kite Pharma, Inc.
  • 10.2.7. Novartis AG
  • 10.2.8. Pfizer Inc.
  • 10.2.9. Sanofi
  • 10.2.10. Spectrum

11. 360 Degree Analyst View

12. Appendix

• 12.1. Research Methodology
• 12.2. References
• 12.3. Abbreviations
• 12.4. Disclaimer
• 12.5. Contact Us

관련자료